Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! By
Repurposing Fda-Approved Drugs to Find a Novel Inhibitor of Alpha-Ketoglutarate-Dependent Dioxygenase Fto to Treat Esophageal Cancer Publisher



Z Mohammadi ZEINAB ; M Saghaeian Jazi MARIE ; Sm Jafari Seyyed MEHDI ; Sm Mir Seyed MOSTAFA ; J Asadi JAHANBAKHSH ; M Amanlou MASSOUD
Authors

Source: Research in Pharmaceutical Sciences Published:2025


Abstract

Background and purpose: The Fat mass and obesity-associated protein (FTO) plays a significant role in esophageal cancer by regulating N6-methyladenosine (m6A) modification. FTO inhibition has shown potential in cancer therapies but remains underexplored. This study aimed to identify a safer, FDA-approved compound for FTO inhibition that can be used in combination with chemotherapy drugs. Experimental approach: FDA-approved drugs were screened from the Zinc 15 database using AutoDock Vina against the 3D structure of FTO (PDB ID: 3LFM). Discovery Studio software was used to determine binding interactions. The GROMACS package was used for molecular dynamics simulations. A non-toxic concentration was determined through an MTT assay on KYSE-30 esophageal cancer cells. The ELISA assay was used to measure the m6A levels in RNA. Findings/Results: Four compounds, ergotamine, midazolam, digoxin, and loratadine, were identified. Loratadine (ΔG: -8.9) formed stable interactions with FTO, specifically with residues Ser229, Tyr109, Leu109, Val229, and His231. Molecular dynamic simulations of the FTO-loratadine complex revealed higher RMSD fluctuations (0.4-0.6 nm), but the system remained stable overall. RMSF analysis showed similar fluctuation patterns in all three systems, indicating that loratadine did not affect protein structure stability. MM/PBSA calculations revealed powerful binding energy for the FTO-loratadine complex (-135.73 kJ/mol), driven by favorable van der Waals interactions. KYSE-30 cells treated with loratadine (100 μM), m6A levels in KYSE- 30 cells compared to the control group were significantly elevated at a non-toxic concentration. Conclusion and implications: Loratadine is a promising, low-toxic FTO inhibitor that could complement chemotherapy for esophageal cancer. © 2025 Elsevier B.V., All rights reserved.
Related Docs
View other Related Docs
1. Unraveling the Complex Interactions Between the Fat Mass and Obesity-Associated (Fto) Gene, Lifestyle, and Cancer, Advances in Nutrition (2022)
2. Design of a Dual-Function Agent by Fusing a Designed Anti-Vegf-A Binder and Cpg-2 Enzyme, Journal of Biomolecular Structure and Dynamics (2023)
3. Halogenated Derivatives of Cytidine: Structural Analysis and Binding Affnity, Journal of Theoretical and Computational Chemistry (2020)
Experts (# of related papers)
View all Related Experts
Massoud Amanlou (5)
Alireza Foroumadi (4)
Other Related Docs
4. Analysis of B-Rafv600einhibitors Using 2D and 3D-Qsar, Molecular Docking and Pharmacophore Studies, Molecular Diversity (2015)
5. Discovery of Novel and Selective Dna Methyltransferase 1 Inhibitors by Pharmacophore and Docking-Based Virtual Screening, ChemistrySelect (2017)
6. Imidazo[1,2-A]Quinazolines As Novel, Potent Egfr-Tk Inhibitors: Design, Synthesis, Bioactivity Evaluation, and in Silico Studies, Bioorganic Chemistry (2023)
7. Drug Repurposing for Targeting Fibronectin in Treatment of Endometriosis and Cancers, Journal of Biomolecular Structure and Dynamics (2023)
8. Novel Quinazolin-4(3H)-One Linked to 1,2,3-Triazoles: Synthesis and Anticancer Activity, Chemical Biology and Drug Design (2018)
9. The Effect of Arsenic Trioxide and Its Combination With Oxaliplatin and Docetaxel on the Induction of Autophagy and Expression of Lc3 and Beclin-1 Genes in Ags and Mkn-45 Gastric Cancer Cell Lines, Advanced Pharmaceutical Bulletin (2025)
10. Agonist/Antagonist Compounds' Mechanism of Action on Estrogen Receptor-Positive Breast Cancer: A System-Level Investigation Assisted by Meta-Analysis, Informatics in Medicine Unlocked (2022)
11. Identification of Potential Inhibitors for Poly(Adp-Ribose) Polymerase-10 (Parp10): Virtual Screening, Molecular Docking, and Molecular Dynamics Simulations, ChemistrySelect (2024)
12. Design, Synthesis, Docking Studies, and Biological Activity of Novel Analogs of Cyclophosphamide As Potential Anticancer Agents, Current Medicinal Chemistry (2025)
13. Synthesis, Molecular Docking, and Biological Evaluation of Pyridin-3-Yl-Pyrimidin-2-Yl-Triazole Derivatives As Anti-Cancer Agents, Polycyclic Aromatic Compounds (2024)
14. Novel Quinazolines Bearing 1,3,4-Thiadiazole-Aryl Urea Derivative As Anticancer Agents: Design, Synthesis, Molecular Docking, Dft and Bioactivity Evaluations, BMC Chemistry (2024)
15. Discovery of Novel Dual Inhibitors Against Mdm2 and Mdmx Proteins by in Silico Approaches and Binding Assay, Life Sciences (2016)
16. Design, Synthesis and Biological Evaluation Of4-(Imidazolylmethyl)- 2-(4-Methylsulfonyl Phenyl)-Quinoline Derivatives As Selective Cox-2 Inhibitors and In-Vitro Anti-Breast Cancer Agents, Iranian Journal of Pharmaceutical Research (2016)
17. Combined Virtual Screening, Dft Calculations and Molecular Dynamics Simulations to Discovery of Potent Mmp-9 Inhibitors, Letters in Drug Design and Discovery (2019)
18. The Obeticholic Acid Can Positively Regulate the Cancerous Behavior of Mcf7 Breast Cancer Cell Line, Molecular Biology Reports (2024)
19. Binding Mode of Triazole Derivatives As Aromatase Inhibitors Based on Docking, Protein Ligand Interaction Fingerprinting, and Molecular Dynamics Simulation Studies, Research in Pharmaceutical Sciences (2017)
20. Targeting the Microrna Binding Domain of Argonaute 2: Rational Inhibitor Design and Study of Mutation Effects on Protein-Ligand Interaction, Journal of Biomolecular Structure and Dynamics (2020)